Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Intestinal organoids and personalized medicine in cystic fibrosis: a successful patient-oriented research collaboration.

Current opinion in pulmonary medicine - 1 Nov 2016

Noordhoek Jacquelien, Gulmans Vincent, van der Ent Kors, Beekman Jeffrey M

Abstract excerpt

PURPOSE OF REVIEW: New therapeutics have been introduced for cystic fibrosis that modulate cystic fibrosis transmembrane conductance regulator (CFTR) function in a mutation-specific fashion. Despite CFTR genotype-based stratification of treatments, treatment efficacy is variable between study participants suggesting that individual factors further contribute to drug efficacy. Moreover, these treatments are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cystic Fibrosis
Share to CFTR gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Mutation

Share to Organoids

Share to Precision Medicine

Source

Identifiers

PMID: 27635627
DOI: 10.1097/MCP.0000000000000315

Genes

CFTR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Intestinal organoids and personalized medicine in cystic fibrosis: a successful patient-oriented research collaboration.PMID 27635627Read ↗

Intestinal organoids for Cystic Fibrosis researchSemantic proximity Read ↗

Patient personalized translational tools in cystic fibrosis to transform data from bench to bed-side and back.Semantic proximity Read ↗

Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis.Semantic proximity Read ↗

Theratyping in cystic fibrosis.Semantic proximity Read ↗

Patient-derived cell models for personalized medicine approaches in cystic fibrosis.Semantic proximity Read ↗

Validating organoid-derived human intestinal monolayers for personalized therapy in cystic fibrosis.Semantic proximity Read ↗

Advances in Preclinical In Vitro Models for the Translation of Precision Medicine for Cystic FibrosisSemantic proximity Read ↗

[News drugs and evolution towards personalized treatment for cystic fibrosis].Semantic proximity Read ↗

Perspectives on the translation of in-vitro studies to precision medicine in Cystic Fibrosis.Semantic proximity Read ↗

Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis.Semantic proximity Read ↗

Personalized medicine for cystic fibrosis: establishing human model systems.Semantic proximity Read ↗

FDA-Approved Drug Screening in Patient-Derived Organoids Demonstrates Potential of Drug Repurposing for Rare Cystic Fibrosis GenotypesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.